NEUROCRINE BIOSCIENCES INC. overview

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum PR Newswire SAN DIEGO, March 11, 2025 SAN DIEGO , March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday , March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference. The live webcast can be accessed on Neurocrine Biosciences' website under Investors at...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO, March 5, 2025 SAN DIEGO , March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an...

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures PR Newswire SAN DIEGO, Feb. 27, 2025 SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of...

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire SAN DIEGO, Feb. 25, 2025 SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano , Chief Financial Officer Matt Abernethy , and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time...

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program PR Newswire SAN DIEGO, Feb. 21, 2025 SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million...

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 PR Newswire SAN DIEGO, Feb. 6, 2025 INGREZZA ® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion , Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA ® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITY TM (crinecerfont), a First-in-Class Treatment for Children...

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results PR Newswire SAN DIEGO, Jan. 30, 2025 Conference Call and Webcast Scheduled for Thursday, February 6 SAN DIEGO , Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on February 6, 2025 . The...

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults PR Newswire SAN DIEGO, Jan. 28, 2025 SAN DIEGO , Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an...